Capricor Therapeutics Sees Unusually High Options Volume (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of unusually large options trading activity on Tuesday. Stock investors purchased 13,044 call options on the company. This is an increase of approximately 748% compared to the average volume of 1,538 call options.

Wall Street Analysts Forecast Growth

CAPR has been the topic of several research reports. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Capricor Therapeutics in a report on Tuesday, September 24th. Maxim Group lifted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Capricor Therapeutics Price Performance

Shares of NASDAQ:CAPR opened at $16.52 on Thursday. The business’s 50 day moving average price is $5.21 and its 200-day moving average price is $5.42. Capricor Therapeutics has a 1 year low of $2.68 and a 1 year high of $18.14. The firm has a market capitalization of $528.29 million, a PE ratio of -18.99 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. As a group, analysts expect that Capricor Therapeutics will post -1.14 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of Capricor Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CAPR. BNP Paribas Financial Markets acquired a new position in Capricor Therapeutics in the first quarter valued at approximately $40,000. Main Street Financial Solutions LLC lifted its stake in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after purchasing an additional 9,040 shares during the period. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics during the 2nd quarter worth about $147,000. Finally, Renaissance Technologies LLC raised its holdings in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.